Genmab Completes $1.8 Billion Acquisition of ProfoundBio, Secures Rights to Promising Cancer Treatments

Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clini...

May 22, 2024 | Wednesday | News
Sandoz's Wyost® and Jubbonti® Gain EC Approval as Biosimilar Versions of Xgeva® and Prolia®

Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC a...

May 22, 2024 | Wednesday | News
OSE Immunotherapeutics and Boehringer Ingelheim Broaden Partnership to Include New CRM and Cancer Therapies

OSE Immunotherapeutics and Boehringer Ingelheim announced a major expansion of their partnership. Two new projects to develop first-in-class treatments wi...

May 22, 2024 | Wednesday | News
Oncolytics Biotech® Teams Up with GCAR to Advance Adaptive Trial for Pancreatic Cancer Treatment

Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOB...

May 15, 2024 | Wednesday | News
FogPharma® and ARTBIO Announce Collaboration to Develop Next-Generation Cancer Therapies

FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...

May 14, 2024 | Tuesday | News
Photocure's Partner Asieris Pharmaceuticals Advances Cevira® for Potential Approval in China

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...

May 13, 2024 | Monday | News
Revance Launches DAXXIFY® for Cervical Dystonia Treatment in U.S. Market

This innovative therapy, the first and only peptide-formulated, long-lasting neurotoxin of its kind, presents a compelling option for patients and physicia...

May 13, 2024 | Monday | News
Zai Lab's AUGTYRO™ Approved by NMPA in China for ROS1-Positive NSCLC Treatment

Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ ...

May 13, 2024 | Monday | News
CytomX Therapeutics Collaborates with MSD for First-in-Human Trial of Novel CX-801 Cytokine to Revolutionize Cancer Treatment

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...

May 08, 2024 | Wednesday | News
High Response Rate in Marginal Zone Lymphoma Patients: Initial Data Shows ZYNLONTA® Efficacy

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...

May 06, 2024 | Monday | News
Astellas Pharma and Poseida Therapeutics Forge Research Collaboration to Develop Novel CAR-T Cell Therapies for Solid Tumors

Astellas Pharma  and Poseida Therapeutics, Inc.   announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos")...

May 02, 2024 | Thursday | News
Abzena Introduces EpiScreen® 2.0: Transforms Immunogenicity Assessment for Advanced Therapeutics

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScree...

April 29, 2024 | Monday | News
Cidara Therapeutics Strikes $128 Million Deal to Divest rezafungin, Bolstering Focus on Cloudbreak Development

  Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...

April 25, 2024 | Thursday | News
EXO Biologics Raises EUR 16M for Exosome Therapy Development

    EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...

April 24, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in